Sagent Pharmaceuticals names new executive

SCHAUMBURG - Sagent Pharmaceuticals has hired Frank Harmon as executive vice president, global operations.

Harmon will oversee Sagent's global operations including product development, R&D, manufacturing, supply chain, regulatory and global alliance management, with oversight support of quality assurance. Harmon will report directly to Allan Oberman, Sagent's chief executive officer.

"Mr. Harmon joins Sagent at an exciting time as we begin to execute against our "Triple E" strategy which is focused on accelerating our growth and enhancing our operational performance," said Oberman. "Frank's extensive experience in pharmaceutical manufacturing and operations, with a proven history of success operating multiple injectable facilities, improving margins and managing complicated supply chains, will play an important role in accelerating our long-term growth trajectory and capitalizing on the favorable market opportunities that we see as critical to long-term value creation."

Harmon has close to 40 years of pharmaceutical operations experience with companies including Fresenius Kabi, Cardinal Health, and Aventis-Behring (formerly Centeon LLC). Most recently, he served as vice president, operations of Nesher Pharmaceuticals, a wholly owned subsidiary of Zydus Pharmaceuticals, where he was responsible for all manufacturing and contract packaging operations for generic solid dose and oral liquid products.

Prior to joining Nesher, Harmon served as chief operating officer and executive vice president of Fresenius Kabi USA, where he was responsible for managing a global network of parenteral manufacturing facilities and its global supply chain including supply from some of Sagent's current partners. He earned an MBA degree from St. Louis University and holds a bachelor's degree in Biology and Chemistry from Western Kentucky University.